Epilepsy: pms-TOPIRAMATE is indicated as monotherapy for the management of patients (adults and children six years and older) with newly diagnosed epilepsy.
pms-TOPIRAMATE is also indicated as adjunctive therapy for the management of patients (adults and children two years and older) with epilepsy who are not satisfactorily controlled with conventional therapy.
Migraine Prophylaxis: pms-TOPIRAMATE is indicated in adults for the prophylaxis of migraine headache. Prophylactic treatment of migraine may be considered in situations such as: adults experiencing four or more migraine attacks per month who fail to respond adequately to acute abortive therapy; recurring attacks that significantly interfere with the patient's daily routine; a pattern of increasing migraine attacks over time, with the risk of developing rebound headache from acute abortive therapies; or failure of, or contraindication to, or troublesome side effects from acute abortive medications. Continuing therapy should be reviewed every six months.
pms-TOPIRAMATE should not be used in the acute treatment of migraine attacks. Safety and efficacy of topiramate in the management or prevention of cluster headache, hemiplegic, basilar, ophthalmoplegic, or transformed migraine headaches have not been established.
Geriatrics (> 65 years of age): There is limited information in patients over 65 years of age (see Use in the Elderly under Precautions).
Pediatrics (< 2 years of age): pms-TOPIRAMATE is not indicated in children under two years of age (see Use in Children under Precautions).